NCT02401048 2019-06-27A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory LymphomasPharmacyclics LLC.Phase 1/2 Completed61 enrolled 24 charts
NCT02549651 2019-02-27MEDI4736 Alone and in Combination With Tremelimumab or AZD9150 in Adult Subjects With Relapsed/Refractory DLBCL (D4190C00023)MedImmune LLCPhase 1 Completed32 enrolled